Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2000Arthritis & Rheumatism

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAlison M. BendelePivotECElizabeth S. ChlipalaUniversity of Colorado BoulderJSJ ScherrerNanotherapeutics (United States)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bendele et al. (2000) studied this question.

synapsesocial.com/papers/6a1b5d4edb618aee6aabccdchttps://doi.org/10.1002/1529-0131(200012)43:12<2648::aid-anr4>3.0.co;2-m
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data1999 · 155 citations
  2. 2IL-1αβ Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-α Blockade Only Ameliorates Joint Inflammation1999 · 402 citations